Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC antihistamines

This article was originally published in The Tan Sheet

Executive Summary

Nonprescription Drug Manufacturers Association submits a study to FDA on March 3 that NDMA says supports the efficacy of doxylamine (7.5 mg q.i.d. for two days) in relieving runny nose and sneezing associated with the common cold. According to NDMA, the new study, in conjunction with previously submitted antihistamine studies, adds further support for the efficacy of all antihistamines in treating common cold symptoms. NDMA also reiterated its request for an "OTC feedback"" meeting to discuss the antihistamine submissions ("The Tan Sheet" March 15, 1993, In Brief
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel